(Q36115739)

12 August 2017

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence (English)

1 reference

12 August 2017

1 reference

1 reference

1 reference

1 reference

Sandercock J

1

1 reference

12 August 2017

Parmar MK

series ordinal

2

1 reference

12 August 2017

Torri V

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 December 1998

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

78

1 reference

12 August 2017

1471-1478

1 reference

12 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.709

12 August 2017

0 references

cites work

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063206

Dose intensity analysis in advanced ovarian cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063206

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063206

Meta-analyses of randomised trials: when the whole is more than just the sum of the parts

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063206

Impact of doxorubicin on survival in advanced ovarian cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063206

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063206

Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063206

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063206

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

23 September 2018

1 reference

12 December 2020

Good manners for the pharmaceutical industry

1 reference

12 December 2020

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

1 reference

12 December 2020

Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis

1 reference

12 December 2020

Chemotherapy for ovarian cancer

1 reference

12 December 2020

Chemotherapy for ovarian cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.709

1 reference

12 August 2017

1 reference

12 August 2017

1 reference